AR019727A1 - Composicion farmaceutica - Google Patents

Composicion farmaceutica

Info

Publication number
AR019727A1
AR019727A1 ARP990103124A ARP990103124A AR019727A1 AR 019727 A1 AR019727 A1 AR 019727A1 AR P990103124 A ARP990103124 A AR P990103124A AR P990103124 A ARP990103124 A AR P990103124A AR 019727 A1 AR019727 A1 AR 019727A1
Authority
AR
Argentina
Prior art keywords
anorexic
insulin sensitizer
treatment
combination
group
Prior art date
Application number
ARP990103124A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AR019727A1 publication Critical patent/AR019727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composicion farmacéutica que comprende un sensibilizador a la insulina en combinacion con un anoréxico. El sensibiizador a la insulina es un compuestode formula (1 donde R representa un grupo de hidrocarburos o un grupo heterocíclico, cada unode los cuales puede presentarse sustituido; Y representa ungrupo de formula: -CO-, -CH(OH)- o NR3, en el cual R3 representa un grupo alquilo, que se puede presentar sustituido; m es 0 o 1; n es 0, 1 o 2, X representaCH o N; A representa un enlacequím ico o un grupo de hidrocarburo alifático bivalente, que tiene de 1 a 7 átomos de carbono; Q representa oxígeno o azufre; R1representa hidrogeno o un grupo alquilo; el anillo E puede presentar también, de 1 a 4 sustituyentes, que pueden formarun anil lo en combinacion con R1; L y Mrespectivamente, representan hidrogeno o pueden combinarse entre sí para formar un enlace químico; o una de sus sales. Dicho sensibilizador a la insulina escloruro de pioglitazona, troglitazona, rosglitazona o4-[4-[2-( 5-metil-2-feniloxazol -4-il)etoxi]bencil]isoxazolidin-3,5-diona y el anoréxico es un anoréxicocentral, el cual es mazindol. Uso de dicho sensibilizador a la insulina en combinacion con un anoréxico para la fabricacion de una preparacionfarmacéutica, para el tratamiento de la diabetes. Dicha preparacion farmacéutica es tanto util para el tratamiento de las complicaciones de la diabetes como para eltratamiento de la tolerancia deteriorada a la glucosa y la reduccion de los efectoscolaterales de u n sensibilizador a la insulina y/o un anoréxicoadministrado a un mamífero diabético.
ARP990103124A 1998-06-30 1999-06-29 Composicion farmaceutica AR019727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP18370098 1998-06-30

Publications (1)

Publication Number Publication Date
AR019727A1 true AR019727A1 (es) 2002-03-13

Family

ID=16140426

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990103124A AR019727A1 (es) 1998-06-30 1999-06-29 Composicion farmaceutica

Country Status (16)

Country Link
US (2) US6329403B1 (es)
EP (1) EP1093370B1 (es)
KR (1) KR20010043455A (es)
CN (1) CN1305376A (es)
AR (1) AR019727A1 (es)
AT (1) ATE318138T1 (es)
AU (1) AU754740B2 (es)
BR (1) BR9911656A (es)
CA (1) CA2329004C (es)
DE (1) DE69929996T2 (es)
DK (1) DK1093370T3 (es)
ES (1) ES2255316T3 (es)
ID (1) ID27415A (es)
NO (1) NO20006630L (es)
WO (1) WO2000000195A1 (es)
ZA (1) ZA200006262B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
CA2349865C (en) * 1999-06-21 2014-08-19 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
US20030040490A1 (en) * 2000-02-24 2003-02-27 Yasuo Sugiyama Drugs containing combined active ingredients
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
JP2004331500A (ja) * 2001-02-16 2004-11-25 Dainippon Pharmaceut Co Ltd 血中濃度制御製剤
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US20050261362A1 (en) * 2004-03-22 2005-11-24 The Regents Of The University Of California Method of increasing endogenous adiponectin and leptin production
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
JP2002360666A (ja) * 2001-06-11 2002-12-17 Takeda Chem Ind Ltd コバルト合金を用いた打錠用杵臼
AU2002351752A1 (en) 2001-12-29 2003-07-30 Novo Nordisk A/S Combined use of a glp-1 compound and another drug for treating dyslipidemia
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US7101845B2 (en) * 2002-01-31 2006-09-05 Joslin Diabetes Center, Inc. Methods of modulating β cell function
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
EP1388352A1 (en) * 2002-08-08 2004-02-11 Laboratoires Fournier S.A. Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2004078716A1 (en) * 2003-03-03 2004-09-16 Merck & Co. Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists
US20050187266A1 (en) * 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US7008957B2 (en) * 2003-07-25 2006-03-07 Sanofi-Aventis Deutschland Gmbh Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
US7264813B2 (en) 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
CN1925854A (zh) * 2003-11-14 2007-03-07 沃泰克斯药物股份有限公司 可用作atp－结合弹夹转运蛋白调控剂的噻唑和噁唑
WO2005072769A1 (en) * 2004-01-26 2005-08-11 Eli Lilly And Company Use of fgf-21 and thiazolidinedione for treating type 2 diabetes
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US7934562B2 (en) * 2004-12-03 2011-05-03 Vetco Gray Scandinavia As Hybrid control system and method
KR100697983B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 신규 중간체 및 이를 이용한 피오글리타존의 제조방법
KR100697982B1 (ko) * 2005-07-08 2007-03-23 대봉엘에스 주식회사 로시글리타존의 제조방법
US20070129444A1 (en) * 2005-12-06 2007-06-07 Mallinckrodt Inc. Novel weight reduction composition and uses thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080176905A1 (en) * 2007-01-22 2008-07-24 Santiago Ini Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
KR101208326B1 (ko) * 2007-03-30 2012-12-05 티오가 파마슈티칼스, 인코포레이티드 설사-우세형 및 교대형 과민성 장 증후군의 치료를 위한 카파-아편제 작용제
US20090318520A1 (en) 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
WO2012059762A1 (en) * 2010-11-03 2012-05-10 Arecor Limited Novel composition comprising glucagon
US10695294B2 (en) 2012-11-06 2020-06-30 Sigrid Therapeutics Ab Porous silica material for use as a pharmaceutical or dietary active ingredient
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
WO2021119316A1 (en) 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
GB9111426D0 (en) * 1991-05-28 1991-07-17 Ici Plc Chemical compounds
AU2479492A (en) 1991-08-26 1993-03-16 Upjohn Company, The Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
AU712607B2 (en) * 1996-02-02 1999-11-11 Merck & Co., Inc. Method of treating diabetes and related disease states
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Also Published As

Publication number Publication date
DE69929996D1 (de) 2006-04-27
CN1305376A (zh) 2001-07-25
ZA200006262B (en) 2001-11-02
NO20006630L (no) 2001-02-26
US6329403B1 (en) 2001-12-11
ES2255316T3 (es) 2006-06-16
US20020086885A1 (en) 2002-07-04
NO20006630D0 (no) 2000-12-22
CA2329004A1 (en) 2000-01-06
EP1093370B1 (en) 2006-02-22
AU754740B2 (en) 2002-11-21
DK1093370T3 (da) 2006-05-22
DE69929996T2 (de) 2006-11-16
KR20010043455A (ko) 2001-05-25
BR9911656A (pt) 2001-03-20
CA2329004C (en) 2009-04-14
ID27415A (id) 2001-04-05
WO2000000195A1 (en) 2000-01-06
ATE318138T1 (de) 2006-03-15
AU4291499A (en) 2000-01-17
EP1093370A1 (en) 2001-04-25

Similar Documents

Publication Publication Date Title
AR019727A1 (es) Composicion farmaceutica
RU92004433A (ru) Ароматические аминоспиртовые производные, способ их получения и фармацевтическая композиция
ATE63914T1 (de) N6-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
YU50302A (sh) Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
KR930703266A (ko) (-)-[[4-(1,4,5,6-테트라하이드로-4-메틸-6-옥소-3-피리다지닐)페닐]-히드라조노]프로판디니트릴
RU2002104459A (ru) Способы профилактики и лечения, применение усилителей чувствительности к инсулину
KR940019699A (ko) 옥사졸리딘디온 유도체, 그의 제조방법 및 용도
RU94006013A (ru) Производные оксазолидиндиона, их получение и применение
ES539658A0 (es) Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados
NO20004624D0 (no) Benzensulfonamid-derivater og deres anvendelse som medikamenter
DE69915223D1 (de) Neue heterocyclische analoge von diphenylethylenverbindungen
DE69530094D1 (de) Thiazolidindione derivate, ihre herstellung und verwendung
UY28528A1 (es) Nuevos compuestos
KR920021547A (ko) 아졸 유도체
HUP0300140A2 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments
BR9802804A (pt) Compostos benzimidazol, benzoxazol e benzotiazol, processo para sua preparação e composições farmacéuticas contendo os mesmos.
KR920701177A (ko) 3-아릴옥사졸리디논 유도체, 그의 제조 방법 및 그의 치료 용도
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
KR860700250A (ko) 신규 아미딘 화합물
KR890006621A (ko) 항불안제
KR890014542A (ko) 4-치환된 피라졸로[3,4-d] 피리미딘 유도체
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
FI91064B (fi) Menetelmä terapeuttisesti vaikuttavien 3-(N-asyylietyyli-aminoalkyyli)-kromaanien ja -1,4-dioksaanien valmistamiseksi
DK568088A (da) 3,5-dihydroxy-6,8-nonadiensyre-forbindelser og farmaceutiske praeparater indeholdende disse samt 5-hydroxy-3-oxo-6,8-nonadiensyreester-forbindelser til anvendelse som udgangsmateriale ved deres fremstilling
EP1403253A4 (en) NEW HETEROCYCLIC CONNECTION AND THEIR MEDICAL USE

Legal Events

Date Code Title Description
FB Suspension of granting procedure